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Abstract
Background: Deleterious variants in the voltage-gated sodium channel type 2 (Nav1.2) lead to a broad spectrum of
phenotypes ranging from benign familial neonatal-infantile epilepsy (BFNIE), severe developmental and epileptic
encephalopathy (DEE) and intellectual disability (ID) to autism spectrum disorders (ASD). Yet, the underlying
mechanisms are still incompletely understood.
Methods: To further elucidate the genotype-phenotype correlation of SCN2A variants we investigated the
functional effects of six variants representing the phenotypic spectrum by whole-cell patch-clamp studies in
transfected HEK293T cells and in-silico structural modeling.
Results: The two variants p.L1342P and p.E1803G detected in patients with early onset epileptic encephalopathy (EE)
showed profound and complex changes in channel gating, whereas the BFNIE variant p.L1563V exhibited only a small
gain of channel function. The three variants identified in ID patients without seizures, p.R937C, p.L611Vfs*35
and p.W1716*, did not produce measurable currents. Homology modeling of the missense variants predicted
structural impairments consistent with the electrophysiological findings.
Conclusions: Our findings support the hypothesis that complete loss-of-function variants lead to ID without
seizures, small gain-of-function variants cause BFNIE and EE variants exhibit variable but profound Nav1.2
gating changes. Moreover, structural modeling was able to predict the severity of the variant impact, supporting a
potential role of structural modeling as a prognostic tool. Our study on the functional consequences of SCN2A variants
causing the distinct phenotypes of EE, BFNIE and ID contributes to the elucidation of mechanisms underlying the
broad phenotypic variability reported for SCN2A variants.
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Background
SCN2A (OMIM 182390) encodes the pore-forming
α-subunit of the voltage gated sodium channel type 2
(Nav1.2). It is predominantly expressed at the axon ini-
tial segment and nodes of Ranvier of excitatory neurons
of the central nervous system and plays a crucial role for
axon potential initiation and propagation in early develop-
ment (Kaplan et al. 2001, Kole and Stuart 2012). At age
1–2 years, it is partially replaced by Nav1.6 (encoded by
SCN8A) and its main function is then thought to be re-
lated to the support of backpropagating action potentials
(Hu et al. 2009, Sanders et al. 2018). Variants in SCN2A
were initially identified as disease cause in patients with
generalized epilepsy with febrile seizures plus (GEFS+)
(Sugawara et al. 2001) and benign familial neonatal-infant-
ile epilepsy (BFNIE) (Heron et al. 2002). In recent years,
SCN2A has been recognized as one of the most frequently
mutated genes in neurodevelopmental disorders including
autism spectrum disorders (ASD), intellectual disability
(ID), developmental and epileptic encephalopathy (DEE)
and schizophrenia (Li et al. 2016).
Given the broad clinical spectrum associated with
pathogenic variants in this gene, understanding the
genotype-phenotype correlation is a prerequisite for
proper treatment and genetic counselling. To date,
categorization of SCN2A variants by variant type and lo-
cation allows limited prediction of the associated pheno-
type. Causative variants observed in BFNIE and DEE are
usually missense variants clustering in the transmem-
brane segments and short connecting loops (Ben-Shalom
et al. 2017), while more than half of the ASD-associated
SCN2A variants are predicted to introduce a premature
stop codon (Ben-Shalom et al. 2017). However, there are
also reports of patients with nonsense, frameshift and
splice site variants showing a variety of seizure types
(Wolff et al. 2017). Electrophysiological analyses of about
20 pathogenic variants mostly in HEK cells and compu-
tational modeling of neuronal excitability suggest a gain
of channel function and modest neuronal hyperexcitabil-
ity in BFNIE, while DEE pathogenic variants show more
marked and variable gating changes with pronounced
hyper- or hypoexcitability predicted by in-silico model-
ing of six variants (Sugawara et al. 2001, Kamiya et al.
2004, Scalmani et al. 2006, Xu et al. 2007, Misra et al.
2008, Ogiwara et al. 2009, Liao, Anttonen, et al. 2010a,
Liao, Deprez, et al. 2010b, Lossin et al. 2012, Lauxmann
et al. 2013, Schwarz et al. 2016, Wolff et al. 2017,
Berecki et al. 2018, Lauxmann et al. 2018). Gain of func-
tion variants were significantly associated with seizure
onset before 3 months of age and a better response to
sodium channel blockers, while loss of function variants
were more often observed with later onset epilepsy and
no or even adverse responses to sodium channel
blockers (Wolff et al. 2017). One study investigating
SCN2A variants associated with ASD (with or without sei-
zures) in HEK cells showed partial or complete loss of
channel function in all variants (Ben-Shalom et al. 2017).
A recently proposed bidirectional hypothesis suggesting
that gain of channel function leads to epileptic phenotypes
whereas loss of channel function results in ID/ASD
phenotypes (Ben-Shalom et al. 2017, Sanders et al. 2018)
has been challenged by conflicting findings indicating
hypoexcitability in infantile epileptic encephalopathy (EE)
(Berecki et al. 2018). Therefore, characterization of
additional SCN2A variants should help to improve
genotype-phenotype correlation eventually enabling
mechanism-based therapy (Berecki et al. 2018, Sanders et
al. 2018, Ben-Shalom et al. 2017, Wolff et al. 2017).
Here, we investigated the functional consequences of
six SCN2A variants identified in patients with ID without
seizures, early-onset EE or BFNIE using whole-cell
patch-clamp experiments in HEK293T cells transiently
expressing wild-type or mutant Nav1.2. Furthermore, the
description of homologous structures in 2017 (Yan et al.
2017, Shen et al. 2017) allowed us to generate a
3D-model for SCN2A and assess the impact of the dif-
ferent variants on protein structure. We further
re-evaluated the first family reported with a pathogenic
SCN2A variant causing DEE (p.R102*) (Kamiya et al.
2004) which stands out as the only functionally studied
truncating variant leading to DEE.
Methods
Patients and variants
Five previously reported patients carrying a pathogenic
SCN2A variant (Hackenberg et al. 2014, Rauch et al.
2012, Wolff et al. 2017, Papuc et al. 2018) with a pheno-
type of either early-onset EE (n = 2) or ID without sei-
zures (n = 3) were included in this study for functional
and clinical evaluation. One BFNIE variant previously
studied extensively by others was also investigated as a
reference.
Whole exome sequencing
To re-evaluate the DEE case published by Kamiya et al. in
2004 carrying the p.R102* variant detected by targeted se-
quencing of SCN2A, we now performed trio whole exome
sequencing (WES) of this family (see Additional file 1).
Mutagenesis and cell culture
Human SCN2A (‘adult’ isoform (Kasai et al. 2001), RefSeq
NM_021007 (O’Leary et al. 2016)), SCN1B (NM_001037)
and SCN2B (NM_004588) cDNA in pCMV6-XL4/5 ex-
pression vectors were purchased from OriGene (Rockville,
MD, USA). Mutagenesis was performed by Creative Bio-
labs (Shirley, NY, USA) and verified by sequencing.
HEK293T cells (ATCC-LGC Standards, Manassas, VA,
USA) were grown in DMEM supplemented with 9% fetal
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bovine serum and 1% Pen Strep (all Gibco, Carlsbad, CA,
USA). Cells were transiently transfected using Lipofecta-
mine LTX with PLUS Reagent (Invitrogen, Carlsbad, CA,
USA). Wild-type or mutated Nav1.2 α-subunit (1 μg) was
co-expressed with β1- and β2-subunits and EGFP (in a ra-
tio of 1:1:1:0.5, respectively). Recordings were made exclu-
sively from EGFP-positive cells.
Electrophysiology
Whole-cell voltage-clamp recordings were performed at
room temperature 18–30 h after transfection using 2–4
MΩ borosilicate glass pipettes, an EPC7 amplifier and
Patchmaster v2.11 software (HEKA Elektronik Dr. Schulze
GmbH, Lambrecht, Germany). The pipette solution con-
tained (in mM) 110 CsF, 10 NaF, 20 CsCl, 2 EGTA and 10
HEPES ~ 310mOsm (pH 7.35 with CsOH). Bath solution
consisted of (in mM) 145 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2
and 10 HEPES ~ 310mOsm (pH 7.35 with NaOH). Cells
with peak current amplitudes < 0.6 nA were not used for
analysis of biophysical parameters due to possible contam-
ination with endogenous currents of HEK cells. Whole-cell
capacitance was determined by integrating the area under
the capacitive currents in response to a hyperpolarizing
voltage step. Capacitive transients were compensated elec-
tronically. Leak currents were subtracted by use of a P/N
procedure. Sodium currents were evoked by 10ms voltage
steps from − 100mV to + 50mV from a holding potential
of − 120mV. Current densities were obtained by dividing
the peak currents by the capacitance. Charge transfer was
calculated as the area under the current trace and normal-
ized to the capacitance. Sodium conductance (GNa) was cal-
culated as GNa = INa / (Vm −Vrev), where INa is the
measured peak current at the test potential Vm, and Vrev is
the calculated sodium reversal potential. To obtain activa-
tion curves (conductance-voltage relationship), the normal-
ized conductance was plotted against the test potentials
and fitted with a Boltzmann sigmoidal function for quanti-
tative analysis. The 10–90% rise time was obtained from
the I-V current traces. Fast and slow inactivation time con-
stants were obtained by fitting a second order exponential
function to the current decay of the I-V current traces.
Steady-state inactivation was determined using 500ms con-
ditioning prepulses to potentials varying from − 130 to +
10mV followed by a depolarizing test pulse to + 5mV. For
quantitative analysis, normalized peak currents were plotted
against prepulse potential and fitted with a Boltzmann sig-
moidal function. Recovery from fast inactivation was re-
corded by a two-pulse protocol from a holding potential of
− 90mV to + 5mV with increasing interpulse intervals. For
quantitative analyses, the curves were fitted with a first
order exponential function where the tau represents the re-
covery time constant. To analyze use-dependent inactiva-
tion, depolarizing pulse trains from − 90mV to + 10mV at
different frequencies were applied and the residual peak
current of the last pulse was normalized to the peak current
of the first pulse.
Results are presented as mean ± SEM. Statistical signifi-
cance of differences in reference to wild-type was calculated
by using the unpaired Student’s t test and a significance
level of p < 0.05. Data were analyzed using NeuroMatic
v2.00 (Rothman and Silver 2018) within Igor Pro 6.3 soft-
ware (WaveMetrics, Portland, OR, USA) and GraphPad
Prism 7.0 software (GraphPad Software, La Jolla, CA, USA).
Protein modeling
The structure of SCN2A was modeled with Modeller
9.16 (Webb and Sali 2017) using the recently published
structure of a homologous voltage-gated sodium channel
(PDB: 5X0M (Shen et al. 2017)) as template. Residues
440–741 and 990–1184 were excluded from the model-
ing procedure because they were either absent in the
template or they did not exhibit a sufficient sequence
similarity between template and target sequence. RasMol
(Sayle and Milner-White 1995) was used for structure
analysis and visualization.
Results
Patient phenotypes and variants
Comprehensive phenotypes of our patients and bioinfor-
matic annotations of their respective variants are pre-
sented in Table 1 and their location in the 2D-scheme of
the Nav1.2 channel is depicted in Fig. 1. All missense
variants affect a highly conserved amino acid and have
damaging in-silico predictions.
ID mutants are non-conducting
Representative families of whole-cell current traces of
wild-type and conducting mutant channels are shown in
Fig. 2a, while Fig. 2b depicts the peak current amplitude
normalized by cell capacitance for wild-type and mutant
Nav1.2. Recombinant Nav1.2 channels carrying variants
from ID patients showed no or only small residual cur-
rents indistinguishable from endogenous HEK293T cell
currents (Zhu et al. 1998, Cummins et al. 1993) (mean
peak current wild-type = − 1131 ± 190 pA, n = 8; R937C =
− 271 ± 46 pA, n = 9; L611Vfs*35 = − 258 ± 52 pA, n = 10;
W1716* = − 253 ± 45 pA, n = 8). Thus, ID variants re-
sulted in a complete loss of Nav1.2-mediated current. The
mean peak current density of the EE and BFNIE Nav1.2
mutants did not differ significantly from the wild-type
(Fig. 2b, Table 2). Striking alterations were observed in
other functional characteristics as described below.
The EE mutant L1342P shows a hyperpolarizing shift of
activation and inactivation curves
Voltage-dependent activation and inactivation curves of
L1342P exhibited a hyperpolarizing shift of about 15 mV
Begemann et al. Molecular Medicine            (2019) 25:6 Page 3 of 15
Ta
b
le
1
M
ol
ec
ul
ar
da
ta
an
d
pa
tie
nt
ph
en
ot
yp
es
Pa
tie
nt
1
/
ID
Pa
tie
nt
2
/
ID
Pa
tie
nt
3
/
EE
Pa
tie
nt
4
/
ID
Pa
tie
nt
5
/
EE
Pu
bl
is
he
d
BF
N
IE
fa
m
ily
Pr
ev
io
us
pu
bl
ic
at
io
n
Ra
uc
h
et
al
.2
01
2
ER
84
90
Ra
uc
h
et
al
.2
01
2
ZH
60
99
1
H
ac
ke
nb
er
g
et
al
.2
01
4
ZH
62
61
1
W
ol
ff
et
al
.2
01
7
Pa
tie
nt
63
Pa
pu
c
et
al
.2
01
8
ID
42
68
0
H
er
on
et
al
.2
00
2;
Fu
nc
tio
na
lc
ha
ra
ct
er
iz
at
io
n
by
Sc
al
m
an
ie
t
al
.2
00
6,
Xu
et
al
.2
00
7,
M
is
ra
et
al
.2
00
8,
Be
re
ck
ie
t
al
.2
01
8
A
dd
iti
on
al
re
po
rt
s
on
th
e
sa
m
e
va
ria
nt
Li
et
al
.2
01
6
(d
ue
to
a
re
pe
at
sh
ift
de
sc
rib
ed
as
p.
D
60
9f
s)
,I
D
Fu
nc
tio
na
ls
tu
di
es
by
Be
n-
Sh
al
om
et
al
.2
01
7
D
im
as
si
et
al
.2
01
6
M
at
al
on
et
al
.2
01
4
W
ol
ff
et
al
.2
01
7
A
ll
EE
–
–
Ty
pe
of
va
ria
nt
he
t.
fra
m
es
hi
ft
he
t.
m
is
se
ns
e
he
t.
m
is
se
ns
e
he
t.
st
op
he
t.
m
is
se
ns
e
he
t.
m
is
se
ns
e
In
he
rit
an
ce
de
no
vo
de
no
vo
de
no
vo
de
no
vo
de
no
vo
In
he
rit
ed
fro
m
a
pa
re
nt
cD
N
A
le
ve
la
c.
18
31
_1
83
2d
el
C
T
c.
28
09
C
>
T
c.
40
25
T>
C
c.
51
47
G
>
A
c.
54
08
A
>
G
c.
46
87
C
>
G
Pr
ot
ei
n
le
ve
l
p.
(L
61
1V
fs
*3
5)
p.
(R
93
7C
)
p.
(L
13
42
P)
p.
(W
17
16
*)
p.
(E
18
03
G
)
p.
(L
15
63
V)
rs
nu
m
be
r
(d
bS
N
Pb
)
un
re
po
rt
ed
rs
79
60
53
19
7
rs
79
60
53
13
4
un
re
po
rt
ed
un
re
po
rt
ed
rs
12
19
17
75
0
C
hr
om
os
om
al
po
si
tio
n
(h
g1
9)
ch
r2
:1
66
17
98
21
–1
66
17
98
22
ch
r2
:1
66
20
13
11
ch
r2
:1
66
23
12
47
ch
r2
:1
66
24
54
63
ch
r2
:1
66
24
57
24
ch
r2
:1
66
24
33
91
A
lle
le
Fr
eq
ue
nc
y
(G
no
m
A
D
c )
un
re
po
rt
ed
un
re
po
rt
ed
un
re
po
rt
ed
un
re
po
rt
ed
un
re
po
rt
ed
un
re
po
rt
ed
C
on
se
rv
at
io
nd
,
lo
ca
tio
n
in
pr
ot
ei
n
/
hi
gh
,
D
II
S5
–6
hi
gh
,
D
III
S5
/
hi
gh
,
C
-t
er
m
in
us
hi
gh
,
D
IV
S2
Es
ta
bl
is
he
d
Pr
ed
ic
tio
n
to
ol
se
/
pr
ob
ab
ly
da
m
ag
in
g
pr
ob
ab
ly
da
m
ag
in
g
/
pr
ob
ab
ly
da
m
ag
in
g
pr
ob
ab
ly
da
m
ag
in
g
A
ge
at
la
st
in
ve
st
ig
at
io
n
18
y
1m
22
y
9m
6y
8m
24
y
4m
16
y
4m
G
en
de
r
m
al
e
fe
m
al
e
fe
m
al
e
fe
m
al
e
m
al
e
C
on
sa
ng
ui
ni
ty
,e
th
ni
ci
ty
no
,G
er
m
an
no
,S
w
is
s
no
,J
ap
an
es
e/
Sw
is
s
no
,S
w
is
s
no
,S
w
is
s
Pr
e-
or
pe
rin
at
al
an
om
al
ie
s
no
ne
no
ne
no
ne
no
ne
no
ne
G
es
ta
tio
na
la
ge
(w
ee
ks
)
41
40
3/
7
38
5/
7
te
rm
41
1/
7
Bi
rt
h
w
ei
gh
t
/
le
ng
th
/
H
C
36
00
g
/
52
cm
/
35
cm
38
00
g
/
51
cm
/
N
A
29
70
g
/
48
cm
/
36
cm
31
50
g
/
N
A
/
N
A
41
20
g
/
51
cm
/
N
A
In
te
lle
ct
ua
ld
is
ab
ili
ty
ye
s
(IQ
58
)
ye
s
(IQ
<
50
)
ye
s,
se
ve
re
ye
s,
m
ild
re
ad
in
g
ca
pi
ta
ll
et
te
rs
,
ca
lc
ul
at
in
g
w
ith
nu
m
be
rs
up
to
10
ye
s,
se
ve
re
A
ut
is
tic
fe
at
ur
es
ye
s
ye
s
N
A
ye
s
N
A
O
th
er
ab
no
rm
al
be
ha
vi
or
co
m
pu
ls
iv
e
st
er
eo
ty
pi
es
,
au
to
ag
gr
es
si
ve
be
ha
vi
or
co
m
pu
ls
iv
e
st
er
eo
ty
pi
es
,
au
to
ag
gr
es
si
ve
be
ha
vi
or
no
ne
re
cu
rr
en
t
ep
is
od
es
of
m
ut
is
m
an
d
ps
yc
ho
tic
ep
is
od
es
no
ne
D
ev
el
op
m
en
ta
ld
el
ay
Ag
e
of
in
de
p.
w
al
ki
ng
A
ge
of
fir
st
w
or
ds
Sp
ee
ch
de
ve
lo
pm
en
t
ye
s
13
m
12
m
Sp
ea
ks
se
nt
en
ce
s
ye
s
24
m
24
m
Si
m
pl
e
se
nt
en
ce
s
ye
s
no
in
de
p.
si
tt
in
g
or
w
al
ki
ng
- no
sp
ee
ch
ye
s
24
m
de
la
ye
d
ye
s
no
in
de
p.
si
tt
in
g
or
w
al
ki
ng
- no
sp
ee
ch
Se
iz
ur
es
(o
ns
et
)
no
ne
no
ne
ye
s
(d
ia
gn
os
is
at
5
m
)
no
ne
ye
s
(d
ay
3)
Begemann et al. Molecular Medicine            (2019) 25:6 Page 4 of 15
Ta
b
le
1
M
ol
ec
ul
ar
da
ta
an
d
pa
tie
nt
ph
en
ot
yp
es
(C
on
tin
ue
d)
Pa
tie
nt
1
/
ID
Pa
tie
nt
2
/
ID
Pa
tie
nt
3
/
EE
Pa
tie
nt
4
/
ID
Pa
tie
nt
5
/
EE
Pu
bl
is
he
d
BF
N
IE
fa
m
ily
Se
iz
ur
e
ty
pe
/
/
m
yo
cl
on
ic
/
to
ni
c
/
m
yo
cl
on
ic
/
to
ni
c
C
ou
rs
e
of
ep
ile
ps
y
/
/
at
le
as
t
3
se
iz
ur
es
pe
r
da
y,
ph
ar
m
ac
or
es
is
ta
nt
/
1–
7
se
iz
ur
es
pe
r
da
y,
ph
ar
m
ac
or
es
is
ta
nt
A
cq
ui
re
d
m
ic
ro
ce
ph
al
y
no
no
ye
s
no
no
M
us
cl
e
to
ne
ab
no
rm
al
iti
es
,
m
ov
em
en
t
di
so
rd
er
s
no
ne
hy
po
to
ni
a
se
ve
re
hy
po
to
ni
a,
ch
or
eo
at
he
to
tic
m
ov
em
en
ts
no
ne
sp
as
tic
ity
,b
ila
te
ra
l
co
nt
ra
ct
ur
es
of
kn
ee
s
D
ys
m
or
ph
is
m
s
lo
ng
fa
ce
,n
ar
ro
w
pa
lp
eb
ra
l
fis
su
re
s,
an
d
re
la
tiv
el
y
th
ic
k
ey
eb
ro
w
s,
na
rr
ow
pa
la
te
,
in
ve
rt
ed
ni
pp
le
s,
ta
pe
rin
g
fin
ge
rs
lo
ng
fa
ce
,n
ar
ro
w
pa
lp
eb
ra
l
fis
su
re
s,
m
ild
br
ac
hy
m
et
ac
ar
pa
lia
D
ig
.I
V-
V,
ta
pe
rin
g
fin
ge
rs
no
ne
N
A
hi
gh
,n
ar
ro
w
pa
la
te
O
th
er
he
al
th
pr
ob
le
m
s
hy
pe
ro
pi
a
m
yo
pi
a
O
SA
S,
sc
ol
io
si
s,
hi
p
dy
sp
la
si
a
le
ft
,h
ip
su
bl
ux
at
io
n
rig
ht
,
re
cu
rr
in
g
re
sp
ira
to
ry
in
fe
ct
io
ns
no
ne
re
po
rt
ed
co
rt
ic
al
vi
su
al
im
pa
irm
en
t,
ga
st
ro
-
je
ju
na
lt
ub
e
EE
G
no
rm
al
N
A
m
ul
tif
oc
al
sh
ar
p
w
av
e
ac
tiv
ity
,h
yp
sa
rr
hy
th
m
ia
no
rm
al
fro
nt
oc
en
tr
al
sp
ik
e-
w
av
e
ac
tiv
ity
on
bo
th
si
de
s,
bu
rs
t
su
pp
re
ss
io
n
M
RI
pi
ne
al
is
cy
st
N
A
pr
og
re
ss
iv
e
br
ai
n
at
ro
ph
y
no
rm
al
no
rm
al
at
ag
e
4d
,g
en
er
al
iz
ed
su
pr
a-
an
d
in
fra
te
nt
or
ia
l
at
ro
ph
y,
bi
la
te
ra
lh
ip
po
ca
m
pa
l
at
ro
ph
y,
le
ft-
sid
ed
hi
pp
oc
am
pa
ls
cl
er
os
is
an
d
at
ro
ph
y
of
co
rp
us
ca
llo
su
m
at
ag
e
14
y
A
bb
:/
no
t
re
le
va
nt
fo
r
th
is
ca
se
;D
do
m
ai
n,
he
t
he
te
ro
zy
go
us
,E
EG
el
ec
tr
oe
nc
ep
ha
lo
gr
am
,H
C
he
ad
ci
rc
um
fe
re
nc
e,
m
m
on
th
s,
M
RI
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g,
N
A
no
t
av
ai
la
bl
e,
S
se
gm
en
t;
y
ye
ar
s
a a
cc
or
di
ng
to
re
fe
re
nc
e
se
qu
en
ce
N
M
_0
21
00
7
b
ht
tp
s:
//
w
w
w
.n
cb
i.n
lm
.n
ih
.g
ov
/S
N
P
c h
tt
p:
//
gn
om
ad
.b
ro
ad
in
st
itu
te
.o
rg
d
ac
co
rd
in
g
to
A
la
m
ut
Vi
su
al
v.
2.
8.
1
e
Po
ly
ph
en
2,
M
ut
at
io
nT
as
te
r,
SI
FT
as
se
ss
ed
by
A
la
m
ut
Vi
su
al
v.
2.
8.
1
Begemann et al. Molecular Medicine            (2019) 25:6 Page 5 of 15
relative to wild-type (Fig. 2c-e, Table 2). Furthermore,
this mutant showed a slower recovery time constant
from inactivation (Fig. 2g, Table 2) and a trend towards
faster rise time kinetics, although reaching significance
only at − 30mV (Fig. 2i, Additional file 1: Table S1). Dif-
ferences in the current density, decay kinetics and
use-dependent inactivation were not statistically signifi-
cant (Fig. 2b, h and k, Table 2, Additional file 1: Table
S2). Therefore, this mutant showed mixed gain and loss
of function effects.
The EE mutant E1803G exhibits a shallower slope of the
inactivation curve that leads to an increased window
current
While no changes in voltage dependence of activation
were observed for the mutant E1803G compared to
wild-type, the slope of the voltage dependence of inacti-
vation was significantly less steep (Fig. 2c-d, Table 2),
leading to a larger overlap of activation and inactivation
curves. This increased window current suggests the
presence of a persistent current at membrane voltages
between − 45 to − 25 mV (Fig. 2f ). Additionally, the
E1803G mutant tended to have slower activation and
inactivation kinetics (Fig. 2i-k, Additional file 1: Table
S1) and hence tended to let more charge pass com-
pared to wild-type channels (mean charge transfer
normalized to conductance at a test potential of − 10
mV: wild-type = 0.09 ± 0.02 C/F, n = 8; E1803G = 0.16
± 0.03 C/F, n = 8; p = 0.092). The use-dependent in-
activation was similar to wild-type (Fig. 2h, Additional
file 1: Table S2). The larger window current may in-
crease neuronal excitability and thereby promote the
presence of epileptic seizures in affected patients.
The BFNIE mutant L1563V exhibits a small depolarizing
shift of the inactivation curves
Activation, recovery from inactivation, kinetics and
use-dependent inactivation did not show relevant differ-
ences between L1563V and wild-type channels (Fig. 2,
Table 2 and Additional file 1: Tables S1–2). However,
the inactivation curve was slightly but significantly
shifted by about 4 mV in the depolarizing direction (Fig.
2d, Table 2), which suggests a small gain of channel
function.
Structural modeling of the ID variant R937C predicts a
destabilizing effect on the selectivity filter
The α-subunits of voltage-gated sodium channels con-
tain four homologous repeats, which contribute to the
formation of one central pore region (Fig. 3a-b). The
SCN2A pore region contains the typical DEKA motif,
which is formed by four conserved Asp/Glu/Lys/Ala res-
idues (Fig. 3c). These residues represent the sodium se-
lectivity filter and are therefore crucial for channel
function (Shen et al. 2017). The position of one of these
residues (E942) is stabilized by electrostatic interactions
with the adjacent R937 (Fig. 3d). In the R937C variant
these interactions cannot be formed by the shorter and
uncharged cysteine sidechain resulting in a less defined
position of the E942 sidechain. These structural changes
offer an explanation for the electrophysiologically ob-
served loss of conductance.
Structural modeling of the EE variant E1803G supports
altered inactivation properties
Residue E1803 is located in the globular C-terminal do-
main of SCN2A and forms sidechain interactions with
Fig. 1 Schematic drawing of SCN2A indicating the location of studied pathogenic variants. The three patients with ID without seizures carried de
novo heterozygous variants in SCN2A (shown in blue), two of which are nonsense variants (p.L611Vfs*35 and p.W1716*) and one is a missense
variant in the pore-forming loop of domain 2 of the channel (p.R937C). The two patients with early onset EE harbored de novo heterozygous
missense variants (shown in red) in the fifth transmembrane segment of the third channel domain (p.L1342P) or the C-terminal domain
(p.E1803G), respectively. The heterozygous inherited missense variant previously reported by others in a family with BFNIE (Heron et al. 2002)
(shown in green) is located in the second transmembrane segment of domain 4 (p.L1563V). Adapted from Meisler and Kearney (2005)
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two residues of the III-IV domain linker, which cannot
be formed in the E1803G variant (Fig. 3e-f ). The III-IV
linker plays a key role for fast inactivation of voltage-
gated sodium channels (Shen et al. 2017, Yan et al. 2017)
suggesting that an altered interaction with adjacent do-
mains, as observed for the E1803G variant, might affect
inactivation properties.
The EE variant L1342P is predicted to disturb interactions
with the adjacent S4-S5 linker
Residue L1342 is located in helix S4 and the effect of a
L1342P exchange has been assessed previously based on
the isolated helix (Hackenberg et al. 2014) due to the
lack of a homologous 3D-structure at that time. This
previous study revealed the lack of a backbone hydrogen
bond in the mutant resulting in helix destabilization
(Hackenberg et al. 2014). The availability of homologous
structures in 2017 (Yan et al. 2017, Shen et al. 2017)
allowed the generation of a complete 3D-model for
SCN2A and a more comprehensive evaluation of the
effects of the L1342P variant. An inspection of the
SCN2A model reveals that L1342 forms sidechain in-
teractions with W864, which is located in the S4-S5
linker of the adjacent repeat (Fig. 3g). These interac-
tions cannot be formed in the L1342P variant because
the cyclic proline sidechain cannot adopt an extended
conformation required for W864 interaction (Fig. 3h).
Based on this significant structural disturbance and
the observation that a number of disease-related vari-
ants of Nav channels mapped to the interface between
S4 and S5 segments in the neighboring repeats (Shen
et al. 2017, Huang et al. 2017), L1342P is also likely
to affect the biophysical properties of SCN2A.
Hydrophobic interactions within the fourth domain are
expected to be diminished in the L1563V BFNIE variant
Residue L1563 is located in helix S2 of the fourth
voltage-sensing domain and forms hydrophobic sidechain
interactions in the core of the domain (Fig. 3i). In the
L1563V variant some of these hydrophobic interactions
are lost due to the shorter valine sidechain, but the overall
packing of helices S1 and S2 remains unaffected (Fig. 3k).
Thus, this amino acid change is expected to have only a
moderate effect on the local structure of the fourth
domain.
Trio WES in the published DEE patient carrying the R102*
variant did not reveal a second hit
The p.R102* variant is to date the only functionally eval-
uated protein truncating SCN2A variant that leads to an
encephalopathic phenotype with seizures (Kamiya et al.
2004). The reported patch-clamp studies showed a
complete loss of channel function for this variant. This
patient was reported to exhibit intractable seizures with
an onset at age 1y 7m, ASD and severe ID. However, the
mother was also reported to have suffered from recur-
rent febrile seizures until the age of 6y, suggesting the
possibility of a second, maternally inherited variant in an
epilepsy gene to cause the seizures in the patient and
her mother while the de novo truncating SCN2A variant
could explain the ASD/ID phenotype. This hypothesis is
further supported by a recent report of a second patient
carrying this variant (Monies et al. 2017) with a pheno-
type of severe ID and ASD but no seizures at the age of
6.5 years (personal communication Fowzan S. Alkuraya).
To re-evaluate this case, we performed WES in the pa-
tient and her parents and filtered for dominant mater-
nally inherited and recessive rare variants in known
epilepsy and ID genes, as well as de novo variants. How-
ever, we did not detect a likely pathogenic sequence or
copy number variant in any known epilepsy gene other
than the already known SCN2A de novo variant.
Discussion
All three variants from patients with ID without seizures
studied here showed a complete loss of Nav1.2-mediated
currents. While the truncating variant L611Vfs*35 is
likely to result in nonsense mediated mRNA decay
(NMD) in vivo, the stop variant W1716* is located in
the last exon and the mRNA should therefore not be
(See figure on previous page.)
Fig. 2 Patch-clamp recordings in HEK293T cells expressing recombinant Nav1.2 wild-type or mutant channels. Variants E1803G (blue) and L1342P (green)
have been detected in patients with EE, L1563V (red) in a family with BFNIE, and R937C (purple), L611Vfs*35 (orange) and W1716* (light blue) cause ID.
a Family of whole-cell sodium currents of wild-type and conducting mutant Nav1.2. b Peak current amplitudes normalized to cell capacitance (bars are
mean ± SEM) were not significantly different. c Voltage dependence of activation obtained by plotting the normalized conductance against test potentials
and fitted with a Boltzmann function. L1342P showed a significant negative shift (p< 0.001). d Voltage dependence of steady-state inactivation obtained
by displaying the normalized current amplitude against the prepulse potential fitted with a Boltzmann function. A negative shift was observed for both
L1342P (p< 0.001) and L1563 V (p= 0.017), while E1803G had a shallower slope (p< 0.001). e Activation and inactivation curves of L1342P in comparison to
wild-type demonstrating a hyperpolarized shift with unchanged activation-inactivation coupling. f Activation and inactivation curves of E1803G in
comparison to wild-type illustrating the increase of the window current. g Time-dependent recovery from inactivation fitted with a single exponential
function and plotted against a logarithmic time scale. A significantly slower recovery rate was observed in L1342P (p = 0.002). h Use-
dependent inactivation. The frequencies of depolarizing pulse trains are plotted against the residual peak current amplitude of the last
pulse normalized to the peak current amplitude of the first pulse. i 10–90% rise time depicted against test potentials. L1342P exhibited a significantly faster
rise time at the voltage step to − 30mV (p= 0.02). k Fast inactivation time constants plotted against test potentials
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subject to NMD (Sanders et al. 2018), but is expected
to direct the synthesis of a C-terminally truncated
protein. Thus, the complete loss of function in this
mutant must be due to other mechanisms such as
protein instability or disturbed transport. In line with
this concept, Ben-Shalom et al. (2017) showed that in
all three investigated truncating SCN2A variants no
channel could be detected in the membrane of over-
expressing HEK293 cells by immunocytochemistry. Of
note, multiple variants truncating the protein at later
positions (E1777, K1863, I1877) have also been re-
ported to result in complete loss of conductance
(Mantegazza et al. 2001).
It was less apparent how the missense variant R937C
caused a complete loss of function, as the R937C mutant
protein has been previously shown to be correctly lo-
cated in the cell membrane (Ben-Shalom et al. 2017). Its
critical location in the pore loop let us speculate that the
pore could be completely blocked by the amino acid
substitution. Our homology model supports this idea,
predicting that R937 stabilizes the glutamate residue
which is an essential part of the selectivity filter of
Nav1.2. The same structural mechanism also applies to
the previously described R937H variant causing ASD,
which also exhibited no sodium flux (Ben-Shalom et al.
2017). Interestingly, two other variants for which no or
reduced sodium conductance was reported (Ben-Shalom
et al. 2017) are also located in the immediate vicinity of
the DEKA selectivity filter (Fig. 3c). R379H is located
near D384 and T1420M near K1422 of the selectivity fil-
ter. Thus, it is likely that these variants interfere with so-
dium permeability by a mechanism similar to that
deduced above for the R937C variant.
To date, only one other study has functionally evalu-
ated SCN2A variants with a non-epileptic phenotype
(Additional file 1: Table S3) (Ben-Shalom et al. 2017). In
their analysis of variants associated with ASD, all trun-
cating variants and most missense variants were
non-conducting, including R937C also investigated in
our study. Notably, all non-conducting variants were de-
tected in patients without additional seizures.
Both variants causing a phenotype of EE led to pro-
found changes of Nav1.2 channel function. While
L1342P affected several gating properties, E1803G
mainly showed an increased window current caused by a
shallower slope of the inactivation curve. So far, 10
SCN2A variants detected in EE patients have been stud-
ied electrophysiologically (Additional file 1: Table S3)
(Kamiya et al. 2004, Ogiwara et al. 2009, Liao, Anttonen,
et al. 2010, Lossin et al. 2012, Wolff et al. 2017, Berecki
et al. 2018, Lauxmann et al. 2018). Two of them,
E1211K and R1312T, exhibited gating changes similar to
the ones observed in our mutant L1342P with a negative
shift in both activation and inactivation curves and slo-
wed recovery from inactivation (Ogiwara et al. 2009,
Lossin et al. 2012). Interpretation based on these pro-
foundly altered biophysical properties alone is challen-
ging. However, a computational model of a cortical
pyramidal neuron carrying the E1211K variant showed a
marked neuronal hyperexcitability with a hyperpolarized
spike threshold and an increased spike rate (Additional
file 1: Table S4) (Ben-Shalom et al. 2017). We therefore
also assume an increase in excitability for neurons carry-
ing the L1342P variant. To date, three other patients
carrying the de novo variant L1342P have been reported
(Matalon et al. 2014, Dimassi et al. 2016, Wolff et al.
2017). All four affected patients share a common pheno-
type with an early seizure onset between age 3 to 6
months, severe ID, muscle tone abnormalities, (progres-
sive) brain atrophy in MRI, and no eye contact (3/4) or
cortical visual impairment (1/4). The seizures were in-
tractable in 3/4 patients, and the EEG showed hypsar-
rhythmia in all three patients where EEG was reported
and multifocal epileptic activity in 2/3. Acquired micro-
cephaly and choreiform movements were noted in 2/4
patients.
Several missense variants located in the cytoplasmic
C-terminal domain (CTD) leading to EE have been re-
ported (Ben-Shalom et al. 2017). Interestingly, the only
functionally studied variant, R1882Q, was found to have
altered activation and inactivation curves leading to an
increased window current, similar to our findings for
(See figure on previous page.)
Fig. 3 Effect of amino acid exchanges on the SCN2A structure. a Top view on a model of the SCN2A structure. The four homologous repeats are
shown in different colors (blue, cyan, orange, red) and the III-IV domain linker is shown in purple. The site of the pore is marked by a black
diamond and the positions of the missense variants investigated in the present study are indicated. The extracellular sequence stretch spanning
residues 275–359 has been omitted for clarity. b Side-view on the SCN2A structure. Color coding as in (a). c Model of the SCN2A pore region.
The four residues that are critical for Na+ selectivity are shown in stick presentation. d In the wild-type SCN2A (left panel) the sidechain
orientation of E942, which is part of the selectivity filter, is stabilized by polar interactions with R937 (see encircled region). These interactions
cannot be formed in the R937C variant (right panel) by the shorter and uncharged cysteine sidechain thus impeding fixation of the E942
sidechain (flexibility is indicated by the magenta arrow). e E1803 forms interactions with residues Q1510 and P1512 of the III-IV domain linker,
which cannot be formed in the (f) E1803G variant. The lacking interactions are highlighted by a blue dotted circle. g L1342 forms sidechain
interactions with W864 of the adjacent repeat. h In the L1342P variant, these interactions cannot be formed by the less-extended proline
sidechain. i L1563 forms hydrophobic interactions within the fourth domain. k These interactions are partially lost in the L1563V variant by the
shorter valine sidechain (indicated by a blue dotted circle)
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E1803G. Our structural model predicts that the contacts
between the CTD and the inactivation gate are disturbed
(Fig. 3e-f ), providing a mechanistic explanation for the
altered inactivation properties observed in the E1803G
mutant. Interestingly, gating changes leading to a per-
sistent current seem to be a recurrent pathomechanism
for SCN2A variants detected in EE patients, as this dys-
function has also been described previously as the mech-
anism of disease for the EE variants A263V (Liao,
Anttonen, et al. 2010a) and V423L (Wolff et al. 2017).
This pathomechanism was also observed in hippocampal
pyramidal neurons of a Q54 transgenic mouse model
carrying a gain-of-function Scn2a variant and showing a
progressive epilepsy phenotype (Kearney et al. 2001). Per-
sistent currents have been found to substantially influence
action potential thresholds in axons and are considered to
be important for generation of high-frequency action po-
tential bursts in axons and nodes of Ranvier, the main ex-
pression sites of Nav1.2 (Kole and Stuart 2012).
Most previous electrophysiological studies of BFNIE
variants reported a gain-of-function effect, assuming
hyperexcitability as the mechanism of disease
(Additional file 1: Table S3) (Scalmani et al. 2006, Xu et
al. 2007, Misra et al. 2008, Liao, Deprez, et al. 2010b,
Lauxmann et al. 2013, Lauxmann et al. 2018, Berecki et
al. 2018). Our results for the recurrent BFNIE variant
L1563V of a small but significant depolarizing shift of
the inactivation curve expected to result in a small
gain-of-function are in line with previous studies of this
variant (Scalmani et al. 2006, Xu et al. 2007, Misra
et al. 2008, Berecki et al. 2018). Consistent with the
small effect size, molecular modeling (Fig. 3i-k) showed
that the L1563V exchange causes only a small
perturbation of the SCN2A structure. In BFNIE,
seizures are thought to be self-limited due to the
developmental regulation of sodium channels with
Nav1.2 being partially substituted by Nav1.6 (Liao,
Deprez, et al. 2010b, Lauxmann et al. 2013, Sanders
et al. 2018), while the more pronounced impact of DEE
variants on gating properties also observed in this study
suggests continued disturbance of neuronal function
(Ben-Shalom et al. 2017).
Our study of six SCN2A variants representing the
phenotypic variability known for this gene supports
the association of their respective functional impact
with the observed patient phenotype. Our data cor-
roborates the assumption that 1) a loss of channel
function caused by de novo truncating or missense
variants is the underlying mechanism that leads to ID
2) benign epilepsy is due to usually inherited mis-
sense variants that lead to a small but relevant gain
of channel function and 3) epileptic encephalopathies
are the result of profound and lasting gating changes
due to de novo missense variants (Ben-Shalom et al.
2017, Sanders et al. 2018, Berecki et al. 2018). Add-
itionally, we suggest that a complete loss of Nav1.2
conductance is associated with ID/ASD without sei-
zures, as supported by our own data and the results
reported by Ben-Shalom et al. (2017), although like in
our study long-term follow-up is required since sei-
zures may appear later in childhood. This assumption
is in line with data from a heterozygous knock-out
mouse model which did not show a seizure pheno-
type (Planells-Cases et al. 2000, Middleton et al.
2018). However, another study on knock-out mouse
models despite the absence of behavioral seizures
showed very short absence seizures-like patterns in
electrocorticography (Ogiwara et al. 2018), and mul-
tiple truncating SCN2A variants have been reported
in patients with EE that pose exceptions to this prop-
osition (Kamiya et al. 2004, Carvill et al. 2013, Hor-
vath et al. 2016, Moller et al. 2016, Wolff et al. 2017).
These truncating variants, though functionally studied
in only one case (Kamiya et al. 2004), are expected to
result in a complete loss of function and would there-
fore well explain the developmental delay and mental
impairment but not the development of seizures. A
closer look at the respective reports revealed that a
patient reported with moderate ID and seizures be-
tween the age of 4y 7m and 9y by Wolff et al. (2017)
and carrying the variant W1716* is the same patient
reported in this study, who was suspected but never
proven to have seizures of absence type that were
later interpreted as rather being mutistic episodes.
The patient carrying the de novo variant R102* re-
ported with intractable epilepsy, severe ID and ASD
had a mother with recurrent febrile seizures (Kamiya
et al. 2004) suggesting an inherited second hit con-
tributing to the seizure phenotype, albeit not detected
by our WES analysis. Accordingly, the same variant
in an unrelated patient (Monies et al. 2017) with
follow-up until age 6.5 years did not cause any sei-
zures (personal communication Fowzan S. Alkuraya).
The variant R1435* was reported twice as well, once
in a patient with ASD, ID and seizures (Trump et al.
2016) and once in a patient with ID and ASD without
seizures at the last follow-up at age 7y 8m (Wolff et
al. 2017), also suggesting a possible second hit or
other modifier in the first patient. The assumption of
a modifying effect of the genetic background is sup-
ported by two studies where different strains of mice
carrying the same Scn2a variant exhibited differences
in seizure severity (Kearney et al. 2001, Thompson et
al. 2017). In addition, acquired factors such as hyp-
oxia may also impact Nav1.2 function (Plant et al.
2016, Winquist and Cohen 2018).
It has recently been shown that voltage-gated sodium
channels assemble and gate as dimers (Clatot et al.
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2017) and that some pathogenic Nav1.5 variants exert a
dominant-negative effect through impairing trafficking
and gating of the wild-type channel (Clatot et al. 2012,
Clatot et al. 2018). A possible dominant-negative effect
was also discussed for pathogenic Nav1.2 variants since
Kamiya et al. (2004) described a reduced whole-cell so-
dium current when co-expressing the truncating variant
R102* together with wild-type. However, this effect disap-
peared when co-expressing β-subunits. Ben-Shalom et al.
(2017) did not find a dominant-negative effect either when
testing a non-conducting missense variant. Currently it
can only be speculated if some of the variants might exert
a dominant-negative effect and thereby could explain
some outliers of the assumed genotype-phenotype correl-
ation. Hence, this potential pathomechanism should be
kept in mind and addressed in future studies using suit-
able models resembling the heterozygous constellation in
the patient.
Another point to consider regarding the pathomechan-
ism of SCN2A variants is the isoform-dependent effect of
Nav1.2 variants. Next to the ‘adult’ Nav1.2 isoform, which
was used by all previous electrophysiological investiga-
tions utilizing overexpression of human SCN2A as well as
in our study, a ‘neonatal’ isoform exists differing only in a
single amino acid at position 209 of the protein (Kasai et
al. 2001, Gazina et al. 2015). The ‘neonatal’ isoform is
expressed at different levels at birth and then decreases
until levelling at 10–20% of the ‘adult’ isoform at 20 weeks
postnatally in mice (Gazina et al. 2010). Electrophysio-
logical studies indicate that pathogenic variants can exert
different effects in this ‘neonatal’ isoform compared to the
predominantly studied ‘adult’ isoform (Xu et al. 2007,
Liao, Deprez, et al. 2010b).
Conclusions
In conclusion, our work corroborates a strong genotype-
phenotype correlation of deleterious SCN2A variants and
demonstrates that structural modeling can be a useful tool
to predict the severity of the variant impact, suggesting its
potential as a useful and fast tool to support variant inter-
pretation in diagnostics. We further illustrate the mechan-
ism of how missense variants located in the pore-forming
loop can lead to a loss of channel function and how
C-terminally located missense variants can exert a severe
disturbance on Nav1.2 gating properties.
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